

## LILRB4/CD85k/ILT3 Protein, Cynomolgus, Recombinant (His)

### General Information

Synonyms:	LIR5;CD85K;HM18;LILRB4;ILT3;ILT-3
Protein Construction:	Gln22-Glu259
Species:	Cynomolgus
Expression Host:	HEK293 Cells
Accession:	XP_015297198.1
Molecular Weight:	27.2 kDa (predicted). Due to glycosylation, the protein migrates to 35-42 kDa based on Tris-Bis PAGE result.

### QC Testing

Biological Activity:	Immobilized Cynomolgus LILRB4, His Tag at 5µg/ml (100µl/well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 0.38µg/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

LILRB4, also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM). LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.

Reference

Samuel J, et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018: S1525001618303721-.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481